Reports Q4 revenue $190.17M, consensus $188.28M. “We ended 2025 on a strong note, delivering double-digit revenue growth in the fourth quarter on the strength of our clinical volumes and ongoing mix shift toward higher value tests,” stated Tony Zook, CEO of NeoGenomics (NEO). “Notably, NGS grew 23% in Q4 and 22% for the full year, both well ahead of the market growth rate, reflecting our ability to successfully pull innovation through the community channel, where we enjoy a leadership position and where approximately 80% of all cancer care is delivered today.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NEO Upcoming Earnings Report: What to Expect?
- Guardant Health, Jabil, NeoGenomics, Darden, Cormedix Insider Moves
- NeoGenomics: Solid Execution and Clean Quarter Support Fair Valuation, Justifying Hold Amid CFO Transition and Limited Medium-Term Visibility
- NeoGenomics reports preliminary Q4 revenue $190M, consensus $188.07M
- NeoGenomics CFO Jeff Sherman to retire, Abhishek Jain to succeed